HYBRID EVENT: You can participate in person at Tokyo, Japan from your home or work.
Adenoid Cystic Carcinoma (ACC) is a rare and slow-growing form of cancer that typically originates in the salivary glands. Although it can occur in various other locations, such as the breast, lacrimal glands, and respiratory tract, ACC most commonly affects the major and minor salivary glands of the head and neck.
This cancer is characterized by its indolent nature, often progressing slowly over the course of many years. ACC is known for its tendency to infiltrate nerves, leading to complications and challenges in treatment. Despite its slow growth, ACC has a high potential for recurrence and distant metastasis.
ACC is notorious for being resistant to traditional cancer treatments, such as chemotherapy and radiation therapy. Surgical intervention is often the primary mode of treatment, involving the removal of the tumor and surrounding tissues. However, due to the intricate nature of the disease and its propensity to involve critical structures, complete surgical resection can be challenging.
The clinical course of ACC varies widely among individuals, making prognosis difficult to predict. Some cases exhibit a relatively indolent behavior, while others may show aggressive tendencies with a higher risk of metastasis. The long-term management of ACC involves close monitoring, as well as potential adjuvant therapies depending on the extent of the disease.
Research into Adenoid Cystic Carcinoma is ongoing, with a focus on understanding the underlying genetic and molecular factors contributing to its development. This knowledge is crucial for developing targeted therapies that may offer more effective treatment options for individuals diagnosed with ACC.
